Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1220
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1200 to $1220.
August 02, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $1200 to $1220.
The increase in the price target from $1200 to $1220 and the maintained Overweight rating by Barclays is a positive signal for investors, likely leading to a short-term increase in the stock price of Regeneron Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100